Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience

被引：1
|
作者：
Vachhani, Pankit [1 ]
Al Yacoub, Raed [2 ]
Miller, Austin [3 ]
Cronin, Tara [1 ]
Ontiveros, Evelena [1 ,4 ]
Thompson, James [1 ,4 ]
Griffiths, Elizabeth [1 ,4 ]
Wang, Eunice [1 ,4 ]
机构：
[1] Roswell Park Canc Inst, Dept Med, Buffalo, NY 14263 USA
[2] Jacobs Sch Med & Biomed Sci, Dept Med, Buffalo, NY USA
[3] Roswell Park Canc Inst, Dept Biostat & Bioinformat, Buffalo, NY 14263 USA
[4] Roswell Park Canc Inst, Dept Med, Leukemia Serv, Buffalo, NY 14263 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.075
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-172
引用
收藏
页码：S288 / S289
页数：2
相关论文
共 50 条
  • [41] Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients
    Michalski, Joel M.
    Lyden, Elizabeth R.
    Lee, Andrea J.
    Al-Kadhimi, Zaid S.
    Maness, Lori J.
    Gundabolu, Krishna
    Bhatt, Vijaya Raj
    FUTURE ONCOLOGY, 2019, 15 (17) : 1989 - 1995
  • [42] Compared to Venetoclax Plus Hypomethylating Agents, High Dose Cytarabine Based Intensive Chemotherapy Induction for Newly Diagnosed Acute Myeloid Leukemia (AML) Leads to a Faster Remission Resulting in Better Survival
    Solh, Melhem M.
    Solomon, Scott R.
    Morris, Lawrence
    Holland, H. Kent
    Bachier-Rodriguez, Lizamarie
    Zhang, Xu
    Jackson, Katelin C.
    Bashey, Asad
    BLOOD, 2023, 142
  • [43] Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience
    Roldan Perez, Alicia
    Vazquez Paganini, Juan Andres
    Penalva Moreno, M. Jose
    Gimenez Mesa, Eugenio
    Vilches Moreno, Alba Sara
    Nunez-Torron Stock, Claudia
    Herraez Garcia, Regina
    CLINICAL CASE REPORTS, 2022, 10 (07):
  • [44] Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    Chen, Hongli
    Yang, Ruoyu
    Gao, Gongzhizi
    He, Aili
    Wang, Fangxia
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2025, 16
  • [45] Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
    Richard-Carpentier, Guillaume
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [46] Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival
    Karrar, Omer
    Abdelmagid, Maymona
    Rana, Masooma
    Iftikhar, Moazah
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Elliott, Michelle A.
    Mangaonkar, Abhishek
    Saliba, Antoine
    Torghabeh, Mehrdad Hefazi
    Litzow, Mark R.
    Hogan, William
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Palmer, Jeanne
    Sproat, Lisa
    Khera, Nandita
    Yi, Cecilia Arana
    Tefferi, Ayalew
    Gangat, Naseema
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (02) : E63 - E66
  • [47] The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
    Tsimberidou, Apostolia Maria
    Estey, Elihu
    Wen, Sijin
    Pierce, Sherry
    Kantarjian, Hagop
    Albitar, Maher
    Kurzrock, Razelle
    CANCER, 2008, 113 (07) : 1605 - 1613
  • [48] Hypomethylating agents for the treatment of relapsed acute myeloid leukemia after allogeneic blood stem cell transplantation: A single center experience
    Sciume, Mariarita
    Saporiti, Giorgia
    Tagliaferri, Elena
    Fracchiolla, Nicola
    Grifoni, Federica
    Levati, Giorgia
    Baldini, Luca
    Onida, Francesco
    BONE MARROW TRANSPLANTATION, 2019, 54 : 488 - 489
  • [49] HYPOMETHYLATING AGENTS FOR THE TREATMENT OF RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
    Sciume, M.
    Soverini, G.
    Saporiti, G.
    Tagliaferri, E.
    Fracchiolla, N. S.
    Reda, G.
    Grifoni, F.
    Onida, F.
    Cortelezzi, A.
    HAEMATOLOGICA, 2017, 102 : 161 - 161
  • [50] Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification
    Wan, Chao-Ling
    Liu, Yu-Qing
    Liu, Fang-Tong
    Huang, Yuan-Hong
    Cao, Han-Yu
    Huang, Si-Man
    Tan, Kai-Wen
    Ge, Shuai-Shuai
    Wang, Miao
    Liu, Mei-Jing
    Wang, Zi-Hao
    Li, Zheng
    Xue, Sheng-Li
    Dai, Hai-Ping
    BLOOD CANCER JOURNAL, 2024, 14 (01):
12345